tailieunhanh - Báo cáo y học: " Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18 | Au et al. Virology Journal 2011 8 22 http content 8 1 22 J VIROLOGY JOURNAL SHORT REPORT Open Access Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13 A15 and A18 2 1 13 Gough G Au Leone G Beagley Erin S Haley Richard D Barry Darren R Shafren Abstract Many RNA viruses are displaying great promise in the field of oncolytic virotherapy. Previously we reported that the picornavirus Coxsackievirus A21 CVA21 possessed potent oncolytic activity against cultured malignant melanoma cells and melanoma xenografts in mice. In the present study we demonstrate that three additional Group A Coxsackieviruses Coxsackievirus A13 CVA13 Coxsackievirus A15 CVA15 and Coxsackievirus A18 CVA18 also have similar oncolytic activity against malignant melanoma. Each of the viruses grew quickly to high titers in cancer cells expressing ICAM-1 and intratumoral injection of preformed subcutaneous SK-Mel-28 xenografts in mice with CVA13 CVA15 and CVA18 resulted in significant tumor volume reduction. As preexisting immunity could potentially hinder oncolytic virotherapy sera from stage IV melanoma patients and normal controls were tested for levels of protective antibody against the panel of oncolytic Coxsackieviruses. Serum neutralization assays revealed that 3 of 21 subjects possessed low levels of anti-CVA21 antibodies while protective antibodies for CVA13 CVA15 and CVA18 were not detected in any sample. Serum from individuals who were seropositive for CVA21 failed to exhibit cross-neutralization of CVA13 CVA15 and CVA18. From these studies it can be concluded that the administration of CVA13 CVA15 or CVA18 could be employed as a potential multivalent oncolytic therapy against malignant melanoma. Findings Numerous viruses from a diverse range of virus families are being identified for use as oncolytic virotherapy agents. The underlying principle of oncolytic virotherapy is that the specificity of lytic viral infection can be harnessed to destroy .